M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer
Pancreatic cancer is a malignant disease with high mortality and poor prognosis due to lack of early diagnosis and low treatment efficiency after diagnosis. Although Gemcitabine (GEM) is used as the first-line chemotherapeutic drug, chemoresistance is still the major problem that limits its therapeu...
Main Authors: | Yongmei Zhao, Yuanlin Zheng, Yan Zhu, Yi Zhang, Hongyan Zhu, Tianqing Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/9/1493 |
Similar Items
-
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
by: Annalisa Comandatore, et al.
Published: (2022-01-01) -
Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer
by: Jiaqiang Ren, et al.
Published: (2024-05-01) -
An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
by: REN Jiaqiang, et al.
Published: (2024-12-01) -
miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR
by: Ryan N. Fuller, et al.
Published: (2024-06-01) -
GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer
by: Chen Chen, et al.
Published: (2022-07-01)